Indication for pulmonary arterial hypertension (PAH), a life-threatening disorder which severely compromises the function of the lungs and heart. IPO on SWX in April 2000.

Company Info
Country: Switzerland
Industry:    Biotech
Sector: biotechnology
Status: Realized
Vehicle: Genevest

Company website

Endeavour Vision Team
Sven Lingjaerde
© Endeavour Vision SA 2006-2017 Terms & Conditions